Innovations in Intranasal Vaccine Delivery Technology - Needle-free vaccine delivery platforms can solve the problems of stockpiling, cold-chain management, and pandemic preparedness. - BioPharm

ADVERTISEMENT

Innovations in Intranasal Vaccine Delivery Technology
Needle-free vaccine delivery platforms can solve the problems of stockpiling, cold-chain management, and pandemic preparedness.


BioPharm International Supplements


ABSTRACT

Innovative delivery technologies for the needle-free delivery of vaccines by the intranasal route offer advantages to traditional parenteral needle-based delivery systems developed and produced by the vaccine industry. Dry powder intranasal vaccine technologies have recently been developed. In addition, a rapid manufacturing technology platform is described that offers distinct advantages for delivery of liquid vaccines, with future development for a breakthrough in situ aseptic reconstitution technology for freeze-dried or spray-dried vaccine powders. This latter advance offers the potential for eliminating or markedly reducing the need for cold-chain management of vaccines during transport and storage. These new technologies have wide-ranging applications and advantages for the reliable and effective administration of vaccine products.


(MYSTIC PHARMACEUTICALS, INC.)
Successful large-scale immunization of populations around the globe with vaccines calls for a convenient mode of drug delivery with accurate dosing, preferably with limited need for specialized training of health workers. As interest grows in immunizing large segments of the global population with vaccines for widespread diseases such as pandemic influenza, malaria, tuberculosis, and rotavirus infections, comes the pressing need for innovative technologies that can facilitate a more responsive and cost-effective process, and also can circumvent the drawbacks of conventional modes of syringe-based vaccine delivery.

Vaccines for potential bio-threat agents such as anthrax, plague, or Ebola virus infections also necessitate technologies compatible with ease of delivery, stockpiling ability, a rapid manufacturing paradigm, rapid deployment, and under certain high risk conditions, the capability to self-administer. In particular, needle-free methods of vaccine administration are appealing alternatives to injected vaccines in these scenarios.

Needle-based vaccine injections require highly trained health workers and an optimally performing system for effective mass vaccination campaigns. The universal fear of needle sticks is an indicator of the need of convenient and viable alternative modes of delivery. Cold-chain management of vaccines is also often necessary, and lyophilized vaccines necessitate reconstitution in diluents at the time of use under sterile conditions, often in adverse field situations. Oral vaccines or transcutaneous vaccine patches have been used but also have drawbacks such as inconsistent absorption, gastrointestinal degradation, or high cost.

Intranasal delivery of drugs and biologics is a rapidly growing means of medicinal prophylaxis and therapy, and offers compelling advantages as a needle-free approach for testing and demonstrating the efficacy of existing and new drugs and vaccines.1 The nasal mucosa provides a convenient surface for vaccine deposition and for induction of systemic and local mucosal immunity. Recent advances in the development of delivery platforms are in response to the demand for innovative approaches to intranasal vaccine delivery that are safer, can be rapidly manufactured cost effectively, and assure compatibility with a wide range of vaccines and biopharmaceuticals. A key benefit of an intranasal vaccine is its potential to induce both mucosal and humoral immunity.

A distinct advantage of intranasal drug delivery is that drug uptake into the blood circulatory system by absorption through the nasal mucosa can be quite rapid.2,3 Moreover, clinical studies have demonstrated that a rapid local immune response can be achieved within 24–48 hours using intranasal delivery, providing rapid protection against airborne pathogens that enter the body through the respiratory tract. Clinical evidence has also demonstrated that complete systemic immunity can be achieved in significantly less time (days versus weeks) through the intranasal route.

An optimal intranasal drug delivery platform must be designed to provide accurate and precise delivery through optimized device design, such that the amount of drug or vaccine for each dose must be consistent. Advantages of intranasal vaccine delivery versus administration by oral or injection routes include a more rapid circulatory uptake at a lower dose than by parenteral or oral drug delivery, lower cost, avoidance of needles, avoidance of losses caused by intestinal passage for oral drugs and first pass liver metabolism, and greater user compliance. These and other differences can translate to a capability for lower effective doses, more rapid physiological response, and fewer complications caused by a vaccine's adverse effects.

Intranasal delivery of an inactivated influenza vaccine has been reported to have an elevated risk for Bell's palsy.4 However, Centers for Disease Control and Prevention studies of 10 years of clinical data concluded that elevated Bell's palsy risk was also observed for parenteral injection delivery of inactivated flu vaccines, demonstrating that intranasal delivery of vaccines was not associated with any Bell's palsy risk.5


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here